Trial Profile

Topical 5% Imiquimod Cream for Vulvar Paget's Disease: Clinical Efficacy, Safety and Immunological Response

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imiquimod (Primary) ; Lidocaine; Paracetamol; Petrolatum
Indications Extramammary Paget disease
Focus Therapeutic Use
Acronyms Paget trial

Most Recent Events

18 Apr 2022 Results (n=23) assessing efficacy, safety, and quality of life in patients with non-invasive vulvar Paget disease using a standardized treatment schedule with 5% imiquimod cream, published in the American Journal of Obstetrics and Gynecology.
30 Dec 2019 Status changed from active, no longer recruiting to completed.
06 May 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com